Novartis Hit By Canakinumab NSCLC Miss

Interleukin-1 Beta Inhibitor Fails To Improve Survival

The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.

dart
CANOPY-2 misses the target • Source: Shutterstock

Having failed to add a cardiovascular indication for canakinumab, Novartis AG's hopes of progressing the anti-inflammatory agent in oncology have been hit by another failure, this time in a late-stage trial for non-small cell lung cancer (NSCLC).

The Swiss major has revealed that canakinumab in combination with the chemotherapy agent docetaxel did not meet the primary endpoint...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category